Tag: AstraZeneca

B7-H3 Antibody-Drug Conjugates Gain Momentum as Frontline Standards Shift Across Solid Tumors

Advances, Sequencing Challenges, and Real-World Integration of ADCs in Breast Cancer: Insights from ASCO 2026

Datopotamab deruxtecan: First TROP2-Directed ADC Approved for First-Line Treatment of mTNBC in Patients Ineligible for Immunotherapy

Positive topline results from a planned interim analysis of the phase 3 DESTINY-Breast09 (NCT04784715) trial showed trastuzumab deruxtecan (Enhertu®; Daiichi Sankyo and AstraZeneca)* in combination with pertuzumab (Perjeta®; Genentech/Roche) demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to taxane, trastuzumab (Herceptin®; Genentech/Roche) and pertuzumab (THP) as a first-line treatment for patients with human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer.

A first patient has been dosed in the TROPION-Lung12 phase 3 trial (NCT06564844), a global, multicenter, three-arm, open-label phase 3 trial designed to evaluate the efficacy and safety of adjuvant datopotamab deruxtecan (6 mg/kg; Datroway®; Daiichi Sankyo and AstraZeneca; see: ADC Drug Map) in combination with the PD-1/TIGIT bi-specific antibody rilvegostomig* (750 mg) or rilvegostomig monotherapy (750 mg) monotherapy versus observation or standard of care adjuvant chemotherapy regimens.

Earlier this week, during the 15th World ADC in San Diego, CA, the 11th World ADC Awards reunited both newcomers and leaders of the...

AstraZeneca intends to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global supply of its ADC portfolio. ADCs are next-generation treatments that deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody.

What to Expect at World ADC 2024 in London

LaNova Medicines and AstraZeneca have entered into an exclusive license agreement with  for LM-305, a pre-clinical stage antibody-drug conjugate (ADC) targeting G protein-coupled receptor, class C, group 5, member D (GPRC5D).

AstraZeneca has signed an exclusive global license agreement with KYM Biosciences, a joint venture of Keymed Biosciences and Lepu Biopharma, for CMG901.